SynthesisEuropean journal of clinical nutrition2013
Aluminium in parenteral nutrition: a systematic review.
Synthesis in European journal of clinical nutrition, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.Critical reviews in toxicology · 2014Pooled it
- Dietary Aluminium Exposure and Human Health: Sources, Bioavailability, Toxicokinetics, and Health Risk Assessment.Nutrients · 2026Review
- Model-informed exploration of the boundaries of safe aluminium exposure from allergen immunotherapy in children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Electron Microscopy for the Stability Assessment of Parenteral Nutrition Admixtures: Focus on Precipitation.Nutrients · 2024Article
- Article
- Unexpected Serum and Urine Aluminum Concentrations in Pediatric Patients on Home Parenteral Nutrition.Nutrients · 2023Article
- Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.Nutrients · 2023Review
- Determination of aluminum concentrations of parenteral nutrition solutions by HPLC.European journal of clinical nutrition · 2021Article
- Health concerns on provisional tolerable weekly intake of aluminium in children and adults from vegetables in Mandi-Gobindgarh (India).Environmental geochemistry and health · 2020Article
- Oilseeds from A Brazilian Semi-Arid Region: Edible Potential Regarding the Mineral Composition.Foods (Basel, Switzerland) · 2020Article
- Compatibility of Maximum Inorganic and Organic Calcium and Phosphate Content in Neonatal Parenteral Solutions.Scientific reports · 2019Article
- Monitoring of long-term parenteral nutrition in children with intestinal failure.JGH open : an open access journal of gastroenterology and hepatology · 2019Review
- Trace Element Provision in Parenteral Nutrition in Children: One Size Does Not Fit All.Nutrients · 2018Review
- A Filtration System That Greatly Reduces Aluminum in Calcium Gluconate Injection, USP Used to Prepare Parenteral Nutrition Solutions.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2014Article
- Dietary exposure to aluminium and health risk assessment in the residents of Shenzhen, China.PloS one · 2014Article
- New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
- Toxic and Essential Trace Element Content of Commonly Administered Pediatric Oral Medications.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
- Impact of plasma aluminum on neurocognitive outcomes at early school age in children with intestinal failure.Intestinal Failure (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aluminium (Al) toxicity problem in parenteral nutrition solutions (PNS) is decades old and is still unresolved. The aim of this review is to gather updated information about this matter, regarding legislation, manifestations, diagnostics and treatment, patient population at risk and the actions to be taken to limit its accumulation. A structured search using MeSH vocabulary and Title/Abstract searches was conducted in PubMed (http://www.pubmed.gov) up to November 2012. Al is ubiquitous, facilitating its potential for exposure. Nevertheless, humans have several mechanisms to prevent significant absorption and to aid its elimination; therefore, the vast majority of the population is not at risk for Al toxicity. However, when protective gastrointestinal mechanisms are bypassed (for example, parenteral fluids), renal function is impaired (for example, adult patients with renal compromise and neonates) or exposure is high (for example, long-term PNS), Al is prone to accumulate in the body, including manifestations such as impaired neurological development, Alzheimer's disease, metabolic bone disease, dyslipemia and even genotoxic activity. A high Al content in PNS is largely the result of three parenteral nutrient additives: calcium gluconate, inorganic phosphates and cysteine hydrochloride. Despite the legislative efforts, some factors make difficult to comply with the rule and, therefore, to limit the Al toxicity. Unfortunately, manufacturers have not universally changed their processes to obtain a lower Al content of parenteral drug products (PDP). In addition, the imprecise information provided by PDP labels and the high lot-to-lot variation make the prediction of Al content rather inaccurate.
Indexed as
Identifiers
23403874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.